The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles
Open accessAbstract
Glioblastomas belong to the most aggressive human cancers with short survival times. Due to the blood‐brain barrier, they are mostly inaccessible to traditional chemotherapy. We have recently shown that doxorubicin bound to polysorbate‐coated nanoparticles crossed the intact blood‐brain barrier, thus reaching therapeutic concentrations in the brain. Here, we investigated the therapeutic potential of this formulation of doxorubicin in vivo using an animal model created by implantation of 101/8 glioblastoma tumor in rat brains. Groups of 5–8 glioblastoma‐bearing rats (total n = 151) were subjected to 3 cycles of 1.5–2.5 mg/kg body weight of doxorubicin in different formulations, including doxorubicin bound to polysorbate‐coated nanoparticles. The animals were analyzed for survival (% median increase of survival time, Kaplan‐Meier). Preliminary histology including immunocytochemistry (glial fibrillary acidic protein, ezrin, proliferation and apoptosis) was also performed. Rats treated with doxorubicin bound to polysorbate‐coated nanoparticles had significantly higher survival times compared with all other groups. Over 20% of the animals in this group showed a long‐term remission. Preliminary histology confirmed lower tumor sizes and lower values for proliferation and apoptosis in this group. All groups of animals treated with polysorbate‐containing formulations also had a slight inflammatory reaction to the tumor. There was no indication of neurotoxicity. Additionally, binding to nanoparticles may reduce the systemic toxicity of doxorubicin. This study showed that therapy with doxorubicin bound to nanoparticles offers a therapeutic potential for the treatment of human glioblastoma. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
The Statistical Analysis of Failure Time Data
Young, W. R. (1981) · Journal of Quality Technology · doi:10.1080/00224065.1981.11978770 · Cited by 1,666
DeAngelis, L. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440207 · Cited by 1,663
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801
Self-citationPassage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)
Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Ivanov, A. A. (1995) · Brain Research · doi:10.1016/0006-8993(95)00023-j · Cited by 539
Self-citationSignificant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
Gulyaev, A. E., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., & Kreuter, J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018983904537 · Cited by 521
Self-citationKreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S. E., Engelhardt, B., Alyautdin, R., von Briesen, H., & Begley, D. J. (2003) · Pharmaceutical Research · doi:10.1023/a:1022604120952 · Cited by 469
Self-citationAlyautdin, R. N., Petrov, V. E., Langer, K., Berthold, A., Kharkevich, D. A., & Kreuter, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012098005098 · Cited by 352
Self-citationSeymour, L. W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., & Duncan, R. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(94)00514-6 · Cited by 337
Fundarò, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., & Gasco, M. R. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0695 · Cited by 317
Alyautdin, R. N., Tezikov, E. B., Ramge, P., Kharkevich, D. A., Begley, D. J., & Kreuter, J. (1998) · Journal of Microencapsulation · doi:10.3109/02652049809006836 · Cited by 229
Self-citationOlivier, J.-C., Fenart, L., Chauvet, R., Pariat, C., Cecchelli, R., & Couet, W. (1999) · Pharmaceutical Research · doi:10.1023/a:1018947208597 · Cited by 213
Cytotoxic drugs and the CD95 pathway
Friesen, C., Fulda, S., & Debatin, K.-M. (1999) · Leukemia · doi:10.1038/sj.leu.2401333 · Cited by 208
Derouiche, A., & Frotscher, M. (2001) · Glia · doi:10.1002/glia.1120 · Cited by 197
Walter, K. A., Tamargo, R. J., Olivi, A., Burger, P. C., & Brem, H. (1995) · Neurosurgery · doi:10.1227/00006123-199512000-00013 · Cited by 192
Koukourakis, M. I., Koukouraki, S., Fezoulidis, I., Kelekis, N., Kyrias, G., Archimandritis, S., & Karkavitsas, N. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1459 · Cited by 186
Role of microglia in glioma biology
Badie, B., & Schartner, J. (2001) · Microscopy Research and Technique · doi:10.1002/jemt.1125 · Cited by 186
Gelperina, S. E., Khalansky, A. S., Skidan, I. N., Smirnova, Z. S., Bobruskin, A. I., Severin, S. E., Turowski, B., Zanella, F. E., & Kreuter, J. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(01)00456-8 · Cited by 185
Self-citationAlyaudtin, R. N., Reichel, A., Löbenberg, R., Ramge, P., Kreuter, J., & Begley, D. J. (2001) · Journal of Drug Targeting · doi:10.3109/10611860108997929 · Cited by 166
Self-citationLong-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin
Fabel, K., Dietrich, J., Hau, P., Wismeth, C., Winner, B., Przywara, S., Steinbrecher, A., Ullrich, W., & Bogdahn, U. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1936::aid-cncr1712>3.0.co;2-h · Cited by 155
Glial responses to synaptic damage and plasticity
Aldskogius, H., Liu, L., & Svensson, M. A. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991001)58:1<33::aid-jnr5>3.0.co;2-m · Cited by 145
Friese, A. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(99)00073-9 · Cited by 139
Do anticancer agents reach the tumor target in the human brain?
Donelli, M. G., Zucchetti, M., & D’Incalci, M. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686291 · Cited by 137
Survival and prognosis of patients with astrocytoma with atypical or anaplastic features
Nelson, D. F., Nelson, J. S., Davis, D. R., Chang, C. H., Griffins, T. W., & Pajak, T. F. (1985) · Journal of Neuro-Oncology · doi:10.1007/bf02228884 · Cited by 124
Koukouraki, A. M. I. K. S. (2000) · Acta Oncologica · doi:10.1080/028418600430789 · Cited by 122
MR imaging of phagocytosis in experimental gliomas.
Zimmer, C., Weissleder, R., Poss, K., Bogdanova, A., Wright, S. C., & Enochs, W. S. (1995) · Radiology · doi:10.1148/radiology.197.2.7480707 · Cited by 121
Roullin, G., Deverre, J.-R., Lemaire, L. P., Hindré, F., Venier‐Julienne, M., Vienet, R., & Benoît, J. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00011-5 · Cited by 105
Geiger, K. D., Stoldt, P., Schlote, W., & Derouiche, A. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64816-x · Cited by 98
Self-citationNeuwelt, E. A., Pagel, M. A., Barnett, P. A., et al. (1981) · PubMed · Cited by 97
Trần, Wolz, Egensperger, Kösel, Imai, Bise, Kohsaka, Mehraein, & Graeber (1998) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1998.00120.x · Cited by 94
Perego, P., Corna, E., Cesare, M. D., Gatti, L., Polizzi, D., Pratesi, G., Supino, R., & Zunino, F. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373994 · Cited by 91
Doxorubicin-induced cell death in highly invasive human gliomas.
Stan, A. C., Casares, S. A., Radu, D., Walter, G. F., & Brumeanu, T. (1999) · PubMed · Cited by 71
Immune infiltrates and cytokines in gliomas
Giometto, B., Bozza, F., Faresin, F., Alessio, L., Mingrino, S., & Tavolato, B. F. (1996) · Acta Neurochirurgica · doi:10.1007/bf01411724 · Cited by 69
Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas
von Holst, H., Knochenhauer, E., Blomgren, H., Collins, V. P., Ehn, L., Lindquist, M., Norén, G., & Peterson, C. (1990) · Acta Neurochirurgica · doi:10.1007/bf01842886 · Cited by 62
LIPOSOMAL DAUNORUBICIN (DAUNOXOME) IN CHILDREN WITH RECURRENT OR PROGRESSIVE BRAIN TUMORS
Lippens, R. J. J. (1999) · Pediatric Hematology and Oncology · doi:10.1080/088800199277452 · Cited by 52
Liposomal distribution in malignant glioma
KHALIFA, A., Dodds, D., Rampling, R., PATERSON, J., & Murray, T. J. (1997) · Nuclear Medicine Communications · doi:10.1097/00006231-199701000-00005 · Cited by 44
Schackert, G., Fan, D., Nayar, R., et al. (1989) · Selective Cancer Therapeutics · doi:10.1089/sct.1989.5.73 · Cited by 28
Liposomes as Carriers of Cisplatin into the Central Nervous System
Shibata, S., Akira, O. C. H. I., & Mori, K. (1990) · Neurologia medico-chirurgica · doi:10.2176/nmc.30.242 · Cited by 25
Osmotic Opening of the Blood-Brain Barrier and Brain Tumor Chemotherapy
Robinson, P. J. (1994) · Methods in neurosciences · doi:10.1016/b978-0-12-185291-7.50009-6 · Cited by 3
Controversial role of intracellular iron in the mechanisms of chemically‐induced hepatotoxicity
Badr, M. Z. (1994) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.2570090105 · Cited by 2
(1989) · PubMed
Cited by
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
Nanocarriers’ entry into the cell: relevance to drug delivery
Hillaireau, H., & Couvreur, P. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0053-z · Cited by 1,552
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
Gabathuler, R. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 802
Metadata
- Authors
- Steiniger, S. C. J., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., Severin, S. E., Uhl, R., Kock, M., Geiger, K. D., & Gelperina, S. E.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2004-01-22
- Volume
- 109
- Issue
- 5
- Pages
- 759-767
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2005542583
- Cited by
- 434
- References
- 43
- FWCI
- 11.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.